IP Library › Granted Patent US 12,404,343
Granted Patent B2
US 12,404,343 · App. 17/476,683 · Granted Sep 2, 2025

Humanised anti kallikrein-2 antibody

Inventors: Par Oskar Vilhelmsson Timmermand (Lund, SE); Amanda Thuy Tran (Malmo, SE); Sven-Erik Strand (Lund, SE); Urpo Juhani Lamminmaki (Vanhalinna, FI); Kjell Sjostrom (Lund, SE)
Assignee: Janssen Biotech, Inc.
C07K16/40A61K51/1045A61K51/1075A61K51/1096C07K16/30A61K2039/505C07K2317/24C07K2317/56C07K2317/565C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,404,343
App. No.
17/476,683
Granted
Sep 2, 2025
Kind
B2
Abstract

The present invention provides antibody polypeptides with binding specificity for human kallikrein-2 (hK2), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies. The invention further provides use of said antibody polypeptides in the diagnosis and treatment of prostate cancer.

Claims (35)

1. A method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an antibody polypeptide with binding specificity for human kallikrein-2 (hK2), wherein the antibody polypeptide is an intact antibody and comprises

(a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3; and

(b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6,

and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies.

2. The method according to claim 1 , wherein the prostate cancer is non-localized prostate cancer.

3. The method according to claim 2 , wherein the prostate cancer is metastatic prostate cancer, optionally micrometastatic prostate cancer.

4. The method according to claim 3 , wherein the metastatic prostate cancer is metastases of the lymph system, bone, rectum, bladder, or urethra.

5. The method according to claim 1 , wherein the patient has prostate cancer and is less than 70, 65, 60, 55, 50, 45, or 40 years old at the time of diagnosis of prostate cancer and/or at the time of treatment.

6. The method according to claim 1 , wherein the patient is characterized in that a family member, such as a father or brother, has been previously been diagnosed with prostate cancer.

7. The method according to claim 1 , wherein the prostate cancer is castration-resistant prostate cancer (CRPC).

8. The method according to claim 1 , wherein radio guided surgery is performed on the patient following administration of the antibody polypeptide in order to remove prostate cancer cells.

9. The method of claim 1 , wherein the intact antibody comprises a heavy chain constant region and a light chain constant region of an immunoglobulin G (IgG) molecule.

10. The method of claim 9 , wherein the heavy chain constant region is of an immunoglobulin with a subtype selected from the group consisting of IgG1, IgG2, IgG3 and IgG4.

11. The method of claim 9 , wherein the heavy chain constant region is of an immunoglobulin subtype IgG1.

12. The method of claim 9 , wherein the light chain constant region is of a kappa light chain or lambda light chain.

13. The method of claim 1 , wherein the antibody polypeptide is linked, directly or indirectly, to a therapeutic moiety.

14. The method of claim 13 , wherein the therapeutic moiety is a cytotoxic moiety that comprises or consists of one or more radioisotopes.

15. The method of claim 14 , wherein the one or more radioisotopes is or are each independently selected from the group consisting of beta-emitters, auger-emitters, conversion electron-emitters, alpha-emitters, and low photon energy-emitters.

16. The method of claim 15 , wherein the one or more radioisotopes each independently have an emission pattern of locally absorbed energy that creates a high dose absorbance in the vicinity of the antibody polypeptide.

17. The method of claim 15 , wherein the one or more radioisotopes are each independently selected from the group consisting of long-range beta-emitters; medium range beta-emitters; low-energy beta-emitters; conversion electron-emitters or auger-emitters; and alpha-emitters.

18. The method of claim 13 , wherein the therapeutic moiety is a cytotoxic moiety that comprises or consists of one or more cytotoxic drugs.

19. The method of claim 1 , wherein the antibody polypeptide further comprises a detectable moiety.

20. The method of claim 19 , wherein the detectable moiety comprises or consists of a radioisotope or a paramagnetic isotope.

21. The method of claim 1 , wherein the antibody polypeptide comprises a pair of detectable and cytotoxic radionuclides.

22. The method of claim 21 , wherein the pair of detectable and cytotoxic radionuclides is capable of simultaneously acting in a multi-modal manner as a detectable moiety and also as a cytotoxic moiety.

23. The method of claim 13 , wherein the therapeutic moiety and/or a detectable moiety is joined to the antibody polypeptide indirectly, via a linking moiety.

24. The method of claim 1 , wherein the antibody polypeptide further comprises a moiety for increasing the in vivo half-life of the antibody polypeptide.

25. The method of claim 17 , wherein the long-range beta-emitters comprise 90 Y, 32 P, 186 Re/ 186 Re; 166 Ho, 76 As/ 77 As or 153 Sm.

26. The method of claim 17 , wherein the medium range beta-emitters comprise 131 I, 177 Lu, 67 Cu or 161 Tb.

27. The method of claim 26 , wherein the medium range beta-emitters comprise 177 Lu.

28. The method of claim 17 , wherein the low-energy beta-emitters comprise 45 Ca, 35 S or 14 C.

29. The method of claim 17 , wherein the conversion electron-emitters or auger-emitters comprise 51 Cr, 67 Ga, 99 Tcm, 111 In, 123 I, 125 I or 201 Tl.

30. The method of claim 17 , wherein the alpha-emitters comprise 212 Bi, 213 Bi, 223 AC, 225 AC or 221 At.

31. The method of claim 30 , wherein the alpha-emitters comprise 225 Ac.

32. The method according to claim 4 , wherein the metastases of the bone are metastases within the spine, vertebrae, pelvis, or ribs.

Priority Claims (2)
GB 1320408 · Nov 19, 2013 · national
GB 1401973 · Feb 5, 2014 · national
Continuity (3)
Continuation 16117522 · Aug 30, 2018
Continuation 15036170
Related Publication 20220064333A1 · Mar 3, 2022
References Cited (148)
US 4235871A · Papahadjopoulos et al. · 1980 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5851451A · Takechi et al. · 1998 [cited by applicant]
US 6326471B1 · Kokolus et al. · 2001 [cited by applicant]
US 7053042B1 · Denmeade et al. · 2006 [cited by applicant]
US 7514078B2 · Bander · 2009 [cited by examiner]
US 10100125B2 · Timmermand et al. · 2018 [cited by applicant]
US 20020001588A1 · Sinha · 2002 [cited by applicant]
US 20040101914A1 · Pettersson et al. · 2004 [cited by applicant]
US 20040219163A1 · Frelinger et al. · 2004 [cited by applicant]
US 20050002929A1 · Sanchez-Madrid et al. · 2005 [cited by applicant]
US 20060062793A1 · Webb et al. · 2006 [cited by applicant]
US 20060099204A1 · Couto et al. · 2006 [cited by applicant]
US 20060182682A1 · Ulmert · 2006 [cited by applicant]
US 20090060908A1 · Cardarelli et al. · 2009 [cited by applicant]
US 20100261620A1 · Almagro et al. · 2010 [cited by applicant]
US 20160369009A1 · Timmermand et al. · 2016 [cited by applicant]
CN 101094869A · 2007 [cited by applicant]
CN 101137672A · 2008 [cited by applicant]
EP 0213303A2 · 1987 [cited by applicant]
JP 2008518619A · 2008 [cited by applicant]
JP 2012505654A · 2012 [cited by applicant]
JP 6599859B2 · 2019 [cited by applicant]
WO 9821365A2 · 1998 [cited by applicant]
WO 0112218A1 · 2001 [cited by applicant]
WO 0227323A1 · 2002 [cited by applicant]
WO 0298897A2 · 2002 [cited by applicant]
WO 2003080672A1 · 2003 [cited by applicant]
WO 2006087374A1 · 2006 [cited by applicant]
WO 2008070569A2 · 2008 [cited by applicant]
WO 2008112003A2 · 2008 [cited by applicant]
WO 2013061083A2 · 2013 [cited by applicant]
WO 2023278463A1 · 2023 [cited by applicant]
The abstract of Wang and Shen (Nuclear Medicine Communications, 2012, vol. 33, pp. 379-383) (Year: 2012). [cited by examiner]
The abstract of Bussemakers (European Urology, 1999, vol. 35, pp. 408-412). (Year: 1999). [cited by examiner]
Larsson et al., “Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide … [cited by applicant]
Laune, et al. “Systematic exploration of the antigen binding activity of synthetic peptides isolated from the variable regions of immunoglobulins” J. Biol. Chem. (1997) 272(49):30937-44. [cited by applicant]
Lebeau et al., “Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer”, Biological Chemistry (2010) 391(4):333-43. [cited by applicant]
Leinonen et al., “Epitope mapping of antibodies against prostate-specific antigen with use of peptide libraries”, Clin Chem (2002) 48:2208-16. [cited by applicant]
Leinonen et al., “Reactivity of anti-PSA monoclonal antibodies with recombinant human kallikrein-2”, Tumo Biol. (1999) 20:35-37. [cited by applicant]
Lilja, et al., “Prostate-Specific Antigen in Serum Occurs Predominantly in Complex with a1-Antichymotrypsin” Clin. Chem. (1991) 37(9):1618-1625. [cited by applicant]
Linden et al., “Radioimmunotherapy using 1311-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas”, Clin Cancer Res (1999) 5(10 Suppl):3287s-3291s. [cited by applicant]
Ljungberg et al., “3D absorbed dose calculations based on SPECT: evaluation for 111-In/90-Y therapy using Monte Carlo simulations”, Cancer Biother Radiopharm (2003) 18:99-107. [cited by applicant]
Lovgren, et al., “Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels” Eur. J. Biochem. (1999) 266:1050-1055. [cited by applicant]
Magklara et al., “Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue”, Urology (2000) 56:527-532. [cited by applicant]
Martensson et al., “Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy”, Clin C… [cited by applicant]
Memari et al., “Human Tissue Kallikrein 9: Production of Recombinant Proteins and Specific Antibodies”, Biol. Chem. (2006) 387:733-740. [cited by applicant]
Meyers et al., “Development of monoclonal antibody imaging of metastatic prostatic carcinoma”, Prostate (1989) 14:209-220. [cited by applicant]
Meziere, et al., “In Vivo T Helper Cell Response to Retro-Inverso Peptidomimetics” J. Immunol. (1997) 159 (7):3230-3237. [cited by applicant]
Minarik et al., “90Y Bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy”, J. Nucl. Med (2010) 51:1974-1978. [cited by applicant]
Monnet, et al. “Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells” J. Biol. Chem. (1999) 274(6):3789-96. [cited by applicant]
Nilsson et al., “Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA”, Brit. J Cancer (1997) 75(6):789-797. [cited by applicant]
Nurmikko et al., “Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA”, Clin Chem (2000) 46:1610-1618. [cited by applicant]
Orlova et al., “Cellular processing of (125)I- and (111)in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells”, Nucl Med Biol. (2000) 27:827-835. [cited by applicant]
Oyen et al., “Nuclear medicine techniques for the diagnosis and therapy of prostate carcinoma”, Eur Urol. (2001) 40 (3):294-9. [cited by applicant]
Pajunen, et al., “Cloning, sequencing, expression and characterization of three anti-estradiol-17b Fab fragments” Biochim. Biophys. Acta (1997) 1351:192-202. [cited by applicant]
Palm et al (Journal of Nuclear Medicine, 2003, vol. 44, pp. 1148-1155). (Year: 2003). [cited by applicant]
Paul, “Fundamental Immunology,” 3rd Edition, Raven Press, New York (1993) pp. 292-295. [cited by applicant]
Pessi, et al. “A designed metal-binding protein with a novel fold” Nature (1993) 362(6418):367-9. [cited by applicant]
Pettersson et al., “Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-anti… [cited by applicant]
Piironen et al., “Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing”, Clin Chem. (2001) 47:703-711. [cited by applicant]
Pippin, et al., “Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates” Bioconjug Chem. (1992) 3(4):342-5. [cited by applicant]
Qiu, et al. “Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting” Nat. Biotechnol. (2007) 25(8):921-9. [cited by applicant]
Rittenhouse et al., “Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate” Clin. Lab Sci. (1998) 35:275-368. [cited by applicant]
Rudikoff, et al., “Single amino acid substitution altering antigen-binding specificity” Proc. Natl. Acad. Sci. (1982) 79 (6):1979-1983. [cited by applicant]
Schettino et al., “Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer”, Am J Roentgenol. (2004) 183:519-524. [cited by applicant]
Scott, et al., “Antibody therapy of cancer” Nat. Rev. Cancer (2012) 12(4):278-87. [cited by applicant]
Segars et al., “Development of a 4-D digital mouse phantom for molecular imaging research”, MOL Imaging Biol (2004) 6:149-159. [cited by applicant]
Sgouros et al., “Bone marrow dosimetry for radioimmunotherapy: theoretical considerations”, J. Nucl. Med. (1993) 34:689-694. [cited by applicant]
Siivola et al., “Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections”, Urology (2000) 56:682-688. [cited by applicant]
Sjogreen et al., “The LundADose method for planar image activity quantification and absorbed-dose assessment in radionuclide therapy”, Cancer Biother. Radiopharm. (2005) 20:92-97. [cited by applicant]
Sjogreen-Gleisner et al., “Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibritumomab tiuxetan or [(131)I]tositumomab”, J. Nucl. Med. Mol. Imaging (2011) 55:126-154. [cited by applicant]
Skerra et al., “Alternative non-antibody scaffolds for molecular recognition”, Curr Opin Biotechnol. (2007) 18 (4):295-304. [cited by applicant]
Sklar, et al., “Flow cytometric analysis of ligand-receptor interactions and molecular assemblies” Annu Rev Biophys Biomol Struct. (2002) 31:97-119. [cited by applicant]
Stenman et al., “Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen”, Tumour Biol. (1999) 20:1-12. [cited by applicant]
Strand, et al., “Pharmacokinetic modeling” Med Phys. (1993) 20(2 Pt 2):515-27. [cited by applicant]
Strome (The Oncologist, 2007, vol. 12, pp. 1084-1095). (Year: 2007). [cited by applicant]
Tamura, M., et al., “Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only,” … [cited by applicant]
Taneja et al., “Imaging in the diagnosis and management of prostate cancer”, Rev. Urol. (2004) 6:101-113. [cited by applicant]
Thompson, et al., “Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice” Nucleic Acids Research (1994) 22 (… [cited by applicant]
Thorsett, et al., “Dipeptide mimics. Conformationally restricted inhibitors of angiotensin-converting enzyme” Biochem Biophys Res Commun. (1983) 111(1):166-71. [cited by applicant]
Timmermand, et al., “Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a 111 In-radiolabelled monoclonal antibody, 11B6” EJNMMI Research (2014) 4:51. [cited by applicant]
Torizumi et al., “Evaluation of Serum Prostate Specific Antigen in Diagnosis of Patients with Prostate Cancer”, Radioisotopes (1991) 40:298-301. [cited by applicant]
Tramontano, et al., “Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins” J Mol Biol. (1990) 215(1)175-82. [cited by applicant]
Tremblay et al., “Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors”, Am J Pathology (1997) 150:455-459. [cited by applicant]
U.S. Appl. No. 16/117,522, filed Aug. 30, 2018. [cited by applicant]
U.S. Appl. No. 15/036,170, filed May 12, 2016. [cited by applicant]
Akin et al., “Imaging of prostate cancer”, Radiol Clin North Am. (2007) 45(1):207-22. [cited by applicant]
Almagro, et al., “Humanization of antibodies” Frontiers in Bioscience (2008) 13:1619-1633. [cited by applicant]
Almqvist, et al., “In vitro and in vivo characterization of 177Lu-huA33 A radioimmunoconjugate against colorectal cancer” Nuclear Medicine and Biology (2006) 33:991-998. [cited by applicant]
Angov “Codon usage: Nature's roadmap to expression and folding of proteins” Biotechnol. J. (2011) 6:650-659. [cited by applicant]
Anonymous, Doktorandplats i Medicinsk stralningsfysik, Internet Citation, 2010, 1-2, http://vakanser.se/jobb/doktorandplats+i+medicinsk+stralningsfysik. [cited by applicant]
Armstrong et al., “Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer”, Eur. Urol. (2012) 61(3):549-559. [cited by applicant]
Bapat et al., “Radioiodination of monoclonal antibody for prostate specific antigen”, J. of Radioanalytical and Nuclear Chemistry (2002) 253:227-230. [cited by applicant]
Barbas, et al., “Assembly of combinatorial antibody libraries on phage surfaces: The gene III site” Proc. Natl. Acad. Sci. USA (1991) 88:7978-7982. [cited by applicant]
Bardies, et al., “Quantitative imaging for clinical dosimetry” Nuclear Instruments and Methods in Physics Research A (2006) 569:467-471. [cited by applicant]
Bast et al., “Translational crossroads for biomarkers”, Clin Cancer Res. (2005) 11(17):6103-8. [cited by applicant]
Becker et al., “Sensitive and specific immunodetection of human glandular kallikrein 2 in serum”, Clin Chem (2000) 46:198-206. [cited by applicant]
Bianchi, et al. “High level expression and rational mutagenesis of a designed protein, the minibody. From an insoluble to a soluble molecule” J. Mol. Biol. (1994) 236(2):649-59. [cited by applicant]
Bolch et al., “MIRD Pamphlet No. 21: A generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature”, J. Nuclear Med. (2009) 50:477-484. [cited by applicant]
Borgono et al., “Human tissue kallikreins: physiologic roles and applications in cancer”, Mol Cancer Res. (2004) 2:257-280. [cited by applicant]
Britton et al., “Prostate cancer: the contribution of nuclear medicine,” BJU Int. (2000) 86:135-142. [cited by applicant]
Bunka et al., “Aptamers come of age—at last”, Nature Reviews: Microbiology (2006) 4(8):588-96. [cited by applicant]
Casi, et al., “Antibody-drug conjugates: basic concepts, examples and future perspectives” J. Control Release (2012) 161(2):422-8. [cited by applicant]
Casset, et al., “A Peptide Mimetic of an anti-CD4 Monoclonal Antibody by Rational Design,” Biochem. Biophys. Res. Commun. (2003) 307(1):198-205. [cited by applicant]
Chengazi et al., “Imaging prostate cancer with technetium-99m-7E11-C5.3 (CYT-351)”, Nucl. Med. (1997) 38:675-682. [cited by applicant]
Chothia, et al., “Conformations of immunoglobulin hypervariable regions” Nature (1989) 342(6252):877-883. [cited by applicant]
Darson et al., “Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker”, Urology (1997) 49:857-862. [cited by applicant]
De Pascalis, et al., “Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody” … [cited by applicant]
Diamandis et al., “Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma”, Cancer Research (2002) 62:295-300. [cited by applicant]
Drabovich et al., “Selection of smart aptamers by methods of kinetic capillary electrophoresis,” Anal Chem. (2006) 78(9):3171-8. [cited by applicant]
Ensembl, Transcript: KLK2-201 (ENST00000325321), a product of gene ENSG00000167751. [cited by applicant]
Evans-Axelsson et al., “Targeting Free Prostate-Specific Antigen for In Vivo Imaging of Prostate Cancer Using a Monoclonal Antibody Specific for Unique Epitopes Accessible on Free Prostate-Specific Antigen Alone”, Cance… [cited by applicant]
Feneley et al., “Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer”, Prostate Cancer Prostatic Dis. (2000) 3:47-52. [cited by applicant]
Finlay et al., “Development of a dual monoclonal antibody immunoassay for total human kallikrein 2”, Clin Chem, (2001) 47:1218-1224. [cited by applicant]
Fisher et al., “Generation of Monoclonal Anti Bodi Es Specific For Human Kallikrein 2 (HK2) Using H K2-Expresing Tumors”, Prostate, Wiley-Liss, New York, NY, US, vol. 51, May 15, 2002, pp. 153-165. [cited by applicant]
Foote, et al., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops” J. Mol. Biol. (1992) 224:487-499. [cited by applicant]
Gao, et al. “Molecular cloning of a proteolytic antibody light chain” J. Biol. Chem. (1994) 269(51):32389-93. [cited by applicant]
Garkavij et al., “177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy”, Cancer (2010) 116:1084-1092. [cited by applicant]
GenBank Accession No. AAF08275.1. [cited by applicant]
GenBank Accession No. AAF08277.1. [cited by applicant]
Goldenberg, D.M., “Radiolabelled monoclonal antibodies in the treatment of metastatic cancer” Current Onocology (2007) 14(1):39-42. [cited by applicant]
Hekim et al., “Novel Peptide Inhibitors of Human Kallikrein 2”, J. Biol. Chemistry (2006) 281:12555-12560. [cited by applicant]
Holliger, et al., “Engineered antibody fragments and the rise of single domains” Nat. Biotechnol. (2005) 23 (9):1126-36. [cited by applicant]
Hoppe-Seyler et al., “Peptide aptamers: powerful new tools for molecular medicine”, J. Mol. Med. (2000) 78 (8):426-30. [cited by applicant]
Hricak et al., “Advances in imaging in the postoperative patient with a rising prostate-specific antigen level”, Seminars in Oncology (2003) 30:616-634. [cited by applicant]
Hsieh et al., “Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D”, Cancer Res. (1997) 57:2651-6. [cited by applicant]
Huang, et al., “A Time-Efficient, Linear-Space Local Similarity Algorithm” Adv. Appl. Math. (1991) 12:337-357. [cited by applicant]
Hudson, et al., “Engineered antibodies” Nat. Med. (2003) 9(1): 129-34. [cited by applicant]
Kairemo et al., “Radioimmunotherapy with 90Y-labeled monoclonal antibodies in a nude mouse ovarian cancer model”, Acta Oncology (1993) 32:801-805. [cited by applicant]
Keenan, et al., “RADAR Realistic Animal Model Series for Dose Assessment” J Nucl Med (2010) 51:471-476. [cited by applicant]
Kellof et al., “Challenges in clinical prostate cancer: role of imaging”, AJR (2009) 192:1455-1470. [cited by applicant]
Kim et al., “The unfolding treatment landscape for men with castration-resistant prostate cancer”, Clin. Investig. (2011) 1(11):1533-44. [cited by applicant]
Krebber, et al., “Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system” Journal of Immunological Methods (1997) 201:35-55. [cited by applicant]
Ladner, R.C. “Antibodies cut down to size” Nat. Biotechnol. (2007) 25(8):875-7. [cited by applicant]
Larsson et al., “Monte Carlo calculations of absorbed doses in tumours using a modified MOBY mouse phantom for pre-clinical dosimetry studies”, Acta Oncol. (2011) 50(6):973-80. [cited by applicant]
Larsson et al., “Mouse S-Factors Based on Monte Carlo Simulations in the Anatomical Realistic Moby Phantom for Internal Dosimetry”, Cancer Biother Radiopharm (2007) 22:438-442. [cited by applicant]
Ulmert et al., “Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen”, Cancer Discov. (2012) 2(4):320-7. [cited by applicant]
UniProtKB Accession No. P07288. [cited by applicant]
UniProtKB Accession No. P20151. [cited by applicant]
Vaisanen et al., “Development of sensitive immunoassays for free and total human glandular kallikrein 2”, Clinical Chem. (2004) 50(9):1607-1617. [cited by applicant]
Vaisanen et al., “Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab′)2 fragments” (2006) 78(22):7809-15. [cited by applicant]
Vaisanen et al., Abstract 374: “Sensitive Two-site Immunoassays for Measurement of the Free and Total Forms of Human Glandular Kallikrein 2 (hK2)”, European Urology Supplements (2002) 1(1):96. [cited by applicant]
Van Oosten et al., “Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool”, Translational Oncology (2011) 4:71-82. [cited by applicant]
Vaughan, et al. “Of minibody, camel and bacteriophage” Comb. Chem. High Throughput Screen. (2001) 4(5):417-30. [cited by applicant]
Veber, et al., “Conformationally restricted bicyclic analogs of somatostatin” Proc. Natl. Acad. Sci. (1978) 75 (6):2636-2640. [cited by applicant]
Wenske et al., “Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy”, Int. Journal of Cancer (2009) 124:659-663. [cited by applicant]
Zhu et al., “Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1-antichymotrypsin complex together with free or total PSA”, Clin Chem. (2003) 49:97-103. [cited by applicant]